摘要 目的 观察复方倍他米松并白芍总苷治疗糜烂型口腔扁平苔藓的临床效果。 方法 2015年12月—2016年12月，于青岛市市立医院口腔内科诊治的糜烂型口腔扁平苔藓的病人96例，采用随机数字表法分为3组，每组32例。A组口服白芍总苷胶囊，B组病损黏膜下注射复方倍他米松，C组病损黏膜下注射复方倍他米松并口服白芍总苷胶囊，连续治疗4周后，根据临床治疗效果比较3组的临床疗效、不良反应以及复发率。 结果 B组与C组临床疗效比较，差异无统计学意义（P＞0.05），但均高于A组，差异有显著统计学意义（Z=29.391、23.859,P＜0.05）。A、B、C组病人均未见明显不良反应。随访3月后，A、C组的糜烂复发率明显低于B组，差异具有统计学意义（χ2=9.014、14.034，P＜0.05）。 结论 复方倍他米松并白芍总苷治疗糜烂型口腔扁平苔藓临床效果较好，可提高临床疗效，降低复发率，值得临床推广应用。 Abstract：Objective To investigate the clinical effect of compound betamethasone combined with total glucosides of paeony in the treatment of erosive oral lichen planus. Methods A total of 96 patients with erosive oral lichen planus who were treated in Qingdao Municipal Hospital from December 2015 to December 2016 were enrolled and divided into groups A, B, and C using a random number table, with 32 patients in each group. The patients in group A were given oral administration of total glucosides of paeony capsules, those in group B received submucosal injection of compound betamethasone at the sites of lesions, and those in group C were given submucosal injection of compound betamethasone at the sites of lesions combined with oral administration of total glucosides of paeony capsules. After 4 consecutive weeks of treatment, the three groups were compared in terms of clinical outcome, adverse reactions, and recurrence rate. Results There was no significant difference in clinical outcome between groups B and C (P>0.05), but groups B and C had a significantly better clinical outcome than group A (Z=29.391,23.859,P<0.05). There were no significant adverse reactions in group A, B, or C. After three months of follow-up, groups A and C had a significantly lower recurrence rate of erosion than group B (χ2=9.014,14.034,P<0.05). Conclusion Compound betamethasone combined with total glucosides of paeony has a good clinical effect in the treatment of erosive oral lichen planus and can improve clinical outcome and reduce recurrence rate. Therefore, it holds promise for clinical application
